Stockscreener 앱 받기
11.66
1.66%
0.1876
Replimune Group Inc 주식(REPL)의 최신 뉴스
The week in pharma: action, reaction and insight – week to July 3, 2026 - The Pharma Letter
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
Replimune says FDA rejected its lead drug for skin cancer - MSN
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
REPL Maintains Neutral Rating by Wedbush -- Price Target Raised to $9.00 - GuruFocus
Replimune: Stock Buoyant On Third Try At RP1 ApprovalFDA AdCom May Be Crucial (REPL) - Seeking Alpha
Replimune (REPL) Receives Double Upgrade Amid Positive FDA Devel - GuruFocus
BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 - marketscreener.com
BMO upgrades Replimune stock rating on FDA filing progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $8.17, Implies 30% Downside - TradingView
Replimune's Fiscal Q4 Net Loss Narrows - Moomoo
Replimune gets FDA review for melanoma drug after prior setbacks - The Pharma Letter
Replimune Group Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Replimune Group FY 2026: Revenue $0 Net loss $(313.9)M — 10-K Summary - TradingView
Replimune (NASDAQ: REPL) outlines RP1 melanoma data and high-stakes FDA review - Stock Titan
Replimune Group reports FY2026 net loss $313.9M, cash $268.9M, FDA accepts RP1 BLA resubmission - TradingView
Replimune (REPL) widens FY 2026 loss as FDA accepts RP1 melanoma BLA - Stock Titan
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update - The Manila Times
Replimune’s melanoma drug review moves toward Aug. 2 FDA decision - Stock Titan
Replimune reports fiscal 2026 results and FDA BLA progress for RP1 in melanoma - grafa.com
Replimune Group, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Investors SueWallSt as Replimune Group, Inc. Faces Securities Fraud Allegations - The National Law Review
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - The National Law Review
Replimune upgraded by Analyst with a new price target - Quantisnow
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Replimune (REPL) Receives Upgrade from JPMorgan with Increased P - GuruFocus
Replimune (REPL) Shares Decline After FDA Advisory Committee Ann - GuruFocus
Replimune (REPL) Receives FDA Review for Advanced Melanoma Treat - GuruFocus
Replimune Group, Inc. Stock 12‑Month Price Target Raised to $7.67, Implies 31% Downside - TradingView
Replimune reveals FDA acceptance of resubmitted BLA for RP1 plus nivolumab - grafa.com
FDA accepts Replimune’s resubmitted application for RP1 - Investing.com UK
Replimune Group Inc : JP Morgan Raises to Ove - Moomoo
JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target - marketscreener.com
FDA accepts Replimune’s resubmitted application for RP1 By Investing.com - Investing.com Australia
JPMorgan released its latest research report, significantly upgrading the stock rating of biotechnology company Replimune Group Inc. from "Neutral" to "Overweight." - Bitget
Replimune Group Inc. announced that the U.S. Food and Drug Administration (FDA) has officially accepted its resubmitted Biologics License Application (BLA) for the investigational therapy RP1 for the treatment of advanced melanoma. - Bitget
Replimune Group Stock Short Interest Falls to 54.56% - Quiver Quantitative
Replimune’s RP1 Melanoma Therapy BLA Resubmission Accepted by FDA; Decision Expected August 2026 - Minichart
Enterprise value to EBITDA forward of Replimune Group, Inc. – NASDAQ:REPL - TradingView
Replimune Says FDA Accepts Melanoma Drug Resubmission, Sets Aug. 2 Target Action Date - marketscreener.com
Replimune’s RP1 BLA Resubmission Accepted for Review - TipRanks
Replimune: FDA Accepts RP1 BLA Resubmission with Aug. 2, 2026 Goal Date - TradingView
Replimune to face AdCom panel as lead drug accepted for FDA review - Seeking Alpha
[8-K] Replimune Group, Inc. Reports Material Event - Stock Titan
Replimune Group Announces FDA Acceptance for Review of RP1 BLA Resubmission in Advanced Melanoma - Quiver Quantitative
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma - The Manila Times
FDA accepts Replimune’s melanoma drug review, decision due Aug. 2 - Stock Titan
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services - Yahoo Finance
REPL Forecast — Price Target — Prediction for 2027 - TradingView
Replimune Group, Inc. Actuals & Estimates (SWB:7R8) - TradingView
Replimune Group, Inc. Actuals & Estimates (MUN:7R8) - TradingView
Replimune Group, Inc. Actuals & Estimates (TRADEGATE:7R8) - TradingView
1.83%
3.59%
자본화:
|
볼륨(24시간):